radiopharmaceuticals

News

Clinical results with GEP-NET radioligand therapy AlphaMedix, a possible rival to Novartis' Lutathera, could lead to regulatory filings.

Oncology

Radiopharmaceutical development must move beyond fixed paradigms toward patient-specific, data-driven optimisation.

News

CDMO Nucleus RadioPharma has a high-profile new CEO: former FDA Commissioner and veteran cancer researcher Dr Stephen Hahn.

News

A new player in radioligand therapies, Actithera, has arrived on the scene with $75.5m in funding and lead FAP-targeted candidate for cancer.

News

Bristol Myers Squibb has expanded its push into radiopharma by licensing a prostate cancer therapy developed by Philochem for $350m upfront.

R&D

Players, current and emergent, should prepare for complexities in the supply chain as radiotherapeutics continues to rise.